|Chemical and physical data|
|Molar mass||173.253 g/mol g·mol−1|
|3D model (JSmol)|
Imagabalin (INN, USAN; PD-332,334) is a drug which acts as a ligand for the α2δ subunit of the voltage-dependent calcium channel, with some selectivity for the α2δ1 subunit over α2δ2. Under development by Pfizer as a pharmaceutical medication, it has demonstrated preclinical efficacy of anxiolytic, analgesic, hypnotic, and anticonvulsant-like activity and is currently in phase III clinical trials for the treatment of generalized anxiety disorder.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|